Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Nanjing KATI
Welcome,
Profile
Billing
Logout
Products
Diseases
Products
Trials
News
|
|||||||||
KT095
/
Nanjing KATI
New P1 trial, CAR T-Cell Therapy, Metastases:
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
(clinicaltrials.gov) - Aug 25, 2022
P1
, N=30, Not yet recruiting,
Sponsor: The First People's Hospital of Lianyungang